Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen.
AffiliationActive Biotech Research AB, Box 724, 220 07 Lund, Sweden.
MetadataShow full item record
AbstractSuperantigens activate T-cells by linking the T-cell receptor to MHC class II on antigen-presenting cells, and novel reactivity can be introduced by fusing the superantigen to a targeting molecule. Thus, an antibody-targeted superantigen, which activates T cells to destroy tumour cells, might be used as cancer therapy. A suitable target is the 5T4 oncofetal antigen, which is expressed on many carcinomas. We constructed a fusion protein from a Fab of a monoclonal antibody recognizing the 5T4 antigen, and an engineered superantigen. The recombinant product 5T4FabV13-SEA(D227A)bound the 5T4 antigen expressed on the human non-small-cell lung cancer cell line Calu-1 with a Kd of 1.2 nM while the substitution of Asp227 to Ala in the superantigen moiety reduced binding activity to MHC class II. 5T4FabV13-SEA(D227A)tumour reactivity was demonstrated in 7/7 NSCLC samples by immunohistochemistry, while normal tissue reactivity was low to moderate. 5T4FabV13-SEA(D227A)induced significant T-cell-dependent in vitro killing of sensitive 5T4 bearing Calu-1 cells, with maximum lysis at 10(-10)M, while the capacity to lyse MHC class II expressing cells was approximately 1000 times less effective. Immunotherapy of 5T4FabV13-SEA(D227A)against human NSCLC was investigated in SCID mice reconstituted with human peripheral blood mononuclear cells. Mice carrying intreperitoneally growing Calu-1 cells showed significant reduction in tumour mass and number after intravenous therapy with 5T4FabV13-SEA(D227A). Thus, 5T4FabV13-SEA(D227A)has highly attractive properties for therapy of human NSCLC.
CitationTherapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen. 2001, 85 (1):129-36 Br. J. Cancer
JournalBritish Journal of Cancer
- T-cell immunotherapy for human MK-1-expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody.
- Authors: Ueno A, Arakawa F, Abe H, Matsumoto H, Kudo T, Asano R, Tsumoto K, Kumagai I, Kuroki M, Kuroki M
- Issue date: 2002 Mar-Apr
- A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma.
- Authors: Takemura S, Kudo T, Asano R, Suzuki M, Tsumoto K, Sakurai N, Katayose Y, Kodama H, Yoshida H, Ebara S, Saeki H, Imai K, Matsuno S, Kumagai I
- Issue date: 2002 Mar
- Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma.
- Authors: Tordsson JM, Ohlsson LG, Abrahmsén LB, Karlström PJ, Lando PA, Brodin TN
- Issue date: 2000 Mar
- A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies.
- Authors: Gidlöf C, Dohlsten M, Lando P, Kalland T, Sundström C, Tötterman TH
- Issue date: 1997 Mar 15
- MHC class II-independent, Vbeta-specific activation of T cells by superantigen mutants fused to anti-tumor Fab fragments: implications for use in treatment of human colon carcinoma.
- Authors: Newton DW, Dohlsten M, Lando PA, Kalland T, Olsson C, Kotb M
- Issue date: 1998 Jan